Mustang Bio Seeks 1-for-5 to 1-for-30 Reverse Split to Hold Nasdaq Listing
MBIO is trading near its 52-week low of $0.35 (1.1% above the low).
Summary
Mustang Bio's preliminary proxy asks shareholders to approve a reverse split of 1-for-5 to 1-for-30, aiming to lift the share price back above Nasdaq's $1.00 minimum bid before the April 12, 2027 deadline. Fortress, with about 56.2% of voting power, has committed to vote in favor.
Key Events · Corporate Governance and Compliance · MBIO
-
Reverse Split Put to Shareholder Vote
Proposal Four would amend the charter to effect a reverse split of issued and outstanding common stock at a ratio between 1-for-5 and 1-for-30, with the Board choosing the exact ratio and timing before December 21, 2027.
-
Nasdaq Bid Price Still Deficient
The stock closed at $0.3909 on November 17, 2026, below the $1.00 minimum bid required by Nasdaq Listing Rule 5550(a)(2). The first 180-day window expired October 12, 2026, and the second runs to April 12, 2027.
-
Prior Split Limits Further Grace
Because a 1-for-50 reverse split was effected January 15, 2025, another split within the two-year window would make the company ineligible for any additional compliance period and trigger a Staff delisting determination, subject to a hearings request.
-
Fortress Controls the Outcome
Fortress Biotech holds all 250,000 Class A Preferred shares and 536,577 common shares, about 56.2% of total voting power, and has informed the company it will vote FOR all director nominees and Proposals Two, Three and Four.
Analysis · MBIO · Life Sciences
The stakes are simple: Mustang needs a higher share price to keep its Nasdaq listing. At the December 21, 2026 annual meeting, shareholders will vote on a reverse split of between 1-for-5 and 1-for-30, with the Board choosing the exact ratio and timing any time before December 21, 2027. The stock closed at $0.3909 on November 17, 2026, far below Nasdaq's $1.00 minimum bid. The company already used its first 180-day window, which expired October 12, 2026, and is now running the second, ending April 12, 2027. One hard constraint stands out: because Mustang already did a 1-for-50 reverse split on January 15, 2025, another split inside the two-year window would leave it ineligible for any further compliance period and expose it to a Staff delisting determination. Approval is effectively assured—Fortress Biotech holds roughly 56.2% of the voting power and has said it will vote for all proposals. The real question is whether a higher nominal share price actually attracts buyers. The proxy also covers routine items: seven director nominees, KPMG ratification, and a say-on-pay vote.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBIO was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $0.35 to $1.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.